Keywords: پلاک پسوریازیس; hyperpigmentation; lentigines; macules; plaque psoriasis; ELRP; eruptive lentiginosis in resolving psoriatic plaques; IL; interleukin; TNF; tumor necrosis factor;
مقالات ISI پلاک پسوریازیس (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پلاک پسوریازیس; brodalumab; patient-reported outcome; plaque psoriasis; Psoriasis Symptom Inventory; reliability; validity;
Keywords: پلاک پسوریازیس; Plaque psoriasis; Weight loss; Ketogenic diet; Very low-calorie diet
Keywords: پلاک پسوریازیس; etanercept; long-term safety; open-label; pediatric population; plaque psoriasis; AE; adverse event; CDC; Centers for Disease Control and Prevention; FDA; Food and Drug Administration; HRQOL; health-related quality of life; JIA; juvenile idiopathic arthri
Keywords: پلاک پسوریازیس; Dermatology Life Quality Index; health-related quality of life; patient-reported outcomes; plaque psoriasis; Psoriasis Area and Severity Index; Psoriasis Symptom Inventory; static Physician Global Assessment; DLQI; Dermatology Life Quality Index; HRQoL; h
Keywords: پلاک پسوریازیس; Hypersensitivity reactions; Drug allergy; Anaphylaxis; Biological agents; Monoclonal antibodies; Tryptase; Epinephrine; Skin testing; Rapid desensitization; AS; Ankylosing spondylitis; ASA; Acetylsalicylic acid; BAT; Basophil activation test; CD; Crohn's
The distinct role and regulatory mechanism of IL-17 and IFN-γ in the initiation and development of plaque vs guttate psoriasis
Keywords: پلاک پسوریازیس; Plaque psoriasis; guttate psoriasis; Treg; IFN-γ; IL-17;
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Keywords: پلاک پسوریازیس; anti-IL-17; anti-IL-17A; anti-IL-17F; bimekizumab; biologic therapy; clear or almost clear skin; dose ranging; efficacy; interleukin 17A; interleukin 17F; PASI90; PASI100; phase 2b; plaque psoriasis; randomized clinical trial; safety; AE; adverse event; I
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
Keywords: پلاک پسوریازیس; Asia; Janus kinase inhibitor; Tofacitinib; Plaque psoriasis; Efficacy; Safety;
Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report
Keywords: پلاک پسوریازیس; Metabolic syndrome; Plaque psoriasis; Pro-inflammatory cytokines;
The 3′UTR 1188A/C polymorphism of IL-12p40 is not associated with susceptibility for developing plaque psoriasis in Mestizo population from western Mexico
Keywords: پلاک پسوریازیس; Plaque psoriasis; IL-12B; IL-23 polymorphism
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results
Keywords: پلاک پسوریازیس; adverse events; etanercept; infections; malignancy; plaque psoriasis; registry; safety; surveillance; BSA; body surface area; CI; confidence interval; EMI; event of medical interest; NMSC; nonmelanoma skin cancer; PGA; physician global assessment; SAE; se
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Keywords: پلاک پسوریازیس; clear or almost clear skin; clinical trial; head to head; plaque psoriasis; secukinumab; superiority; ustekinumab; 90% or more improvement in baseline Psoriasis Area and Severity Index; AE; adverse event; DLQI; Dermatology Life Quality Index; HRQoL; healt
Original articlePalmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis
Keywords: پلاک پسوریازیس; epidemiology; health-related quality of life; palmoplantar psoriasis; patient-reported outcomes; plaque psoriasis; psoriasis; BSA; body surface area; CI; confidence interval; DLQI; Dermatology Life Quality Index; EQ-5D; European Quality of Life-5 Dimensio
Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept
Keywords: پلاک پسوریازیس; biologic therapy; etanercept; PASI; plaque psoriasis; PSSI; randomized controlled trial; scalp symptoms; tumor necrosis factor antagonistAE, adverse event; BIW, twice weekly; BMI, body mass index; BSA, body surface area; IL, interleukin; ITT, intent-to-tr
Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010
Keywords: پلاک پسوریازیس; adalimumab; etanercept; infliximab; palmoplantar pustulosis; plaque psoriasis; psoriasis; tumor necrosis factor-α inhibitor
Long-term etanercept in pediatric patients with plaque psoriasis
Keywords: پلاک پسوریازیس; efficacy; etanercept; long-term treatment; pediatric patients; plaque psoriasis; safetyAE, adverse event; ANA, antinuclear antibody; CDLQI, Children's Dermatology Life Quality Index; LOCF, last observation carried forward; OC, observed case; PASI, Psorias
Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis
Keywords: پلاک پسوریازیس; Plaque psoriasis; Macrophages; Dendritic cells; IL-12; IL-23
Phase II randomized, placebo-controlled trial of M. vaccae-derived protein (PVAC®) for the treatment of psoriasis
Keywords: پلاک پسوریازیس; Plaque psoriasis; Treatment; Immunotherapy; PVAC; Placebo